# Carmen Criscitiello

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carmen-criscitiello/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,690 |
| Field | Breast Cancer Treatment Studies |
| h-index | 57 |
| i10-index | 171 |
| Last Known Institution | Humanitas University |
| OpenAlex ID | https://openalex.org/A5000459628 |
| ORCID iD | https://orcid.org/0000-0001-9064-0113 |
| Works | 364 |

## Researcher papers

- [The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014](https://scholariq.org/papers/the-evaluation-of-tumor-infiltrating-lymphocytes-tils-in-breast-cancer/)
- [Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for/)
- [Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-2/)
- [Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study](https://scholariq.org/papers/prognostic-value-of-tumor-infiltrating-lymphocytes-on-residual-disease-after/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Humanitas University](https://scholariq.org/institutions/humanitas-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.